- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced (stage IIIB) or metastatic (stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1090KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 89KB)
Lorlatinib – July 2021
Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua®
Last updated
4 March 2022